Therefore, our results suggest that S100A8/A9 likely has an effect on CLP-induced AKI by impairing Drp1/Mfn1/2-mediated mitochondrial balance, and reducing and suppressing S100A9 may represent a new therapeutic method for septic AKI. This evidence concerns the gene S100A9 and acute kidney injury.